Vivo Capital’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Vivo Capital’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,884,789	Closed	-$1.24M	–	55
2023 Q3	$1.24M	Hold	2,884,789	–	–	0.14%	46
2023 Q2	$3.66M	Hold	2,884,789	–	–	0.25%	40
2023 Q1	$4.04M	Hold	2,884,789	–	–	0.28%	35
2022 Q4	$43.3M	Hold	2,884,789	–	–	4.98%	6
2022 Q3	$14M	Hold	2,884,789	–	–	1.55%	21
2022 Q2	$26.9M	Hold	2,884,789	–	–	2.7%	8
2022 Q1	$18.4M	Hold	2,884,789	–	–	1.27%	18
2021 Q4	$24.9M	Hold	2,884,789	–	–	1.5%	16
2021 Q3	$35.1M	Hold	2,884,789	–	–	1.58%	16
2021 Q2	$25.5M	Buy	+2,884,789	New	+$34.4M	1.11%	22

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Vivo Capital's IMPL Position: Q4 2023 in Review

Vivo Capital sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 2,884,789 shares — an estimated $1.24M sold.

Vivo Capital first reported a position in IMPL in Q2 2021 and held it in 10 quarters. The position peaked at $43.3M in Q4 2022. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

Vivo Capital reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Vivo Capital sold 2,884,789 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $1.24M.
Vivo Capital first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 10 quarters.
Vivo Capital's Impel Pharmaceuticals Inc. Common Stock position peaked at $43.3M in Q4 2022.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Vivo Capital's 13F filing for Q4 2023, filed 7 Feb 2024.